Name (Synonyms) | Correlation | |
---|---|---|
drug22 | 2D Telemedicine Wiki | 0.41 |
drug24 | 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) Wiki | 0.41 |
drug1509 | [TIMP-2]*[IGFBP-7] Wiki | 0.41 |
drug92 | Any drug used to treat Covid-19 Wiki | 0.41 |
drug195 | Blood Transfusion Wiki | 0.41 |
drug41 | AT-527 Wiki | 0.41 |
drug33 | ACEIs Wiki | 0.41 |
drug40 | ASTX660 Wiki | 0.41 |
drug827 | Midazolam Wiki | 0.41 |
drug26 | 3D Telemedicine Wiki | 0.41 |
drug32 | ACE inhibitor, angiotensin receptor blocker Wiki | 0.41 |
drug374 | Conventional treatment Wiki | 0.41 |
drug25 | 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) Wiki | 0.41 |
drug714 | Itraconazole Wiki | 0.29 |
drug1016 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D058186 | Acute Kidney Injury NIH | 0.82 |
D007049 | Iatrogenic Disease NIH | 0.41 |
D007238 | Infarction NIH | 0.24 |
D018746 | Systemic Inflammatory Response Syndrome NIH | 0.24 |
D009102 | Multiple Organ Failure NIH | 0.24 |
D009203 | Myocardial Ischemia NIH | 0.18 |
D014947 | Wounds and Injuries NIH | 0.12 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.08 |
D013577 | Syndrome NIH | 0.05 |
D055371 | Acute Lung Injury NIH | 0.05 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
There are 6 clinical trials
The goal of the proposed study is to determine whether a liberal transfusion strategy (transfusion trigger at Hb < 10 gm/dl) in Veterans at high cardiac risk who undergo major open vascular and general surgery operations is associated with decreased risk of adverse postoperative outcomes compared to a restrictive transfusion strategy (transfusion trigger at Hb < 7 gm/dl).
Description: MI will be defined using the Third Universal Definition of Myocardial Infarction. Acute renal failure will be defined as Acute Kidney Injury stage III according to RIFLE criteria. Baseline creatinine will be considered the creatinine upon admission prior to the index operation. The above urine output criteria will be only used for patients who are in the ICU and have precise monitoring of their urinary output. For patients on the surgical floor only serum creatinine changes will be used for assessment of this endpoint. Coronary revascularization will be defined as a coronary artery bypass graft, or percutaneous coronary intervention (either angioplasty or stenting). Stroke will be defined as new unilateral neurological deficit that lasts for more than 24 hours, and is confirmed by a brain imaging modality (computed tomography or magnetic resonance imaging study) demonstrating new brain infarct.
Measure: A composite endpoint of all-cause post-randomization mortality, myocardial infarction (MI), coronary revascularization, acute renal failure, or post-randomization ischemic stroke up to 90 days after randomization. Time: 90 days after randomizationDescription: Wound infection will be defined according to the Centers for Disease Control and Prevention (CDC) guidelines as a) positive wound culture, or b) drainage of pus from a wound, or c) suspicion of wound infection that was drained operatively. Pneumonia will be defined according to the CDC definition as chest radiograph with new or progressive infiltrate, consolidation, cavitation, or pleural effusion and any of the following: new onset of purulent sputum or change in character of sputum, or organism isolated from blood culture, trans-tracheal aspirate, bronchial brushings, or biopsy. Sepsis will be defined as a combination of two of the following systemic inflammatory response syndrome (SIRS) criteria, plus suspected or present source of infection. SIRS criteria will include the following: temperature greater than 38C, heart rate greater than 90 beats/min, WBC > 12,000 or < 4,000, or > 10% bands.
Measure: A composite endpoint of postoperative infectious complications at 90 days post-randomization: Infectious complications will include wound infections, pneumonia, and sepsis. Time: 90 days after randomizationDescription: The diagnosis of cardiac arrhythmias will be based on EKG findings. Only arrhythmias that result in initiation of new treatment regimen (to include medications, implantable devices, or surgical intervention) during hospitalization will be recorded. CHF will require at least one of the following symptoms or signs new or worsening: dyspnea at rest, orthopnea, or paroxysmal nocturnal dyspnea and radiological evidence of heart failure or worsening heart failure and increase/initiation of established treatment. Cardiac arrest will be defined as the cessation of cardiac pump function activity that results in loss of consciousness and absence of circulating blood flow as evidenced by absent carotid pulse. Only episodes of cardiac arrest that are reversed will be collected under this endpoint. If they are not reversed the event will be categorized as death.
Measure: A composite endpoint of cardiac complications (other than MI) at 90 days post-randomization: Cardiac complications will include new cardiac arrhythmias that necessitate new treatment, new or worsening congestive heart failure (CHF), and cardiac arrest no Time: 90 days after randomizationDescription: The investigators will determine vital status by telephoning participants after hospital discharge, by searching the electronic medical record and the National Death Index.
Measure: All-cause mortality at 1 year after randomization. Time: 12 months after randomizationDescription: MI, coronary revascularization, acute renal failure, or postoperative ischemic stroke.
Measure: A composite endpoint of all-cause mortality, Time: 30 days after randomizationDescription: Length of hospital stay
Measure: Length of hospital stay. Time: At hospital discharge, up to 1 yearDescription: All cause postoperative mortality, Postoperative MI, Postoperative coronary revascularization, Postoperative stroke,Postoperative acute renal failure
Measure: The investigators will examine individual rates of the outcomes that consist of individual components of the primary endpoint. Time: 90 days after randomizationThe outbreak of Covid-19 started several clinical trials and treatment experiments all over the world in the first months of 2020. This study investigates reports of adverse events related to used molecules, including but not limited to protease inhibitors (lopinavir/ritonavir), chloroquine, azithromycin, remdesivir and interferon beta-1a. Analyses of reports also include the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Renal failure Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Heart failure Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: EKG disturbance Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Hepatic failure Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Anemia Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Leucopenia Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Vascular disease Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Toxidermia Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Osteoarticular adverse event Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Death Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Acute respiratory distress syndrome Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020Description: defined by the Medical Dictionary for Regulatory Activities (MeDRA) terms
Measure: Pulmonary embolism or pulmonary hypertension Time: Case reported in the World Health Organization (WHO) database of individual safety case reports to 17/03/2020The kidney may be affected in coronavirus-2019 disease (COVID-19). This study assessed the predictors and outcomes of acute kidney injury (AKI) among individuals with COVID-19.
Description: the incidence of Acute Kidney Injury
Measure: Rate of Acute Kidney Injury Time: From date of admission until the date of discharge or death from any cause, up to 60 daysDescription: death from any cause in the hospital
Measure: Rate of Death Time: From date of admission until the date of death from any cause, up to 60 daysDescription: days from admission to discharge or death
Measure: the length of hospital stay Time: From date of admission until the date of discharge or death from any cause, up to 60 daysThe study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Description: KDIGO AKI score
Measure: Acute Kidney Injury Time: During Intensive Care, an estimated average of 10 days.Description: Acute Respiratory Distress Syndrome yes/no
Measure: ARDS Time: During intensive care, an estimated average of 10 days.Description: Death within 30 days of ICU admission
Measure: 30 day mortality Time: 30 daysDescription: Death within 1 year of ICU admission
Measure: 1 year mortality Time: 1 yearDescription: Development of Chronic Kidney Disease
Measure: Chronic Kidney Disease Time: 60 days and 1 year after ICU admissionDescription: Sequential Organ Failure Score as a continuous variable
Measure: SOFA-score Time: During Intensive Care, an estimated average of 10 days.Acute kidney injury (AKI) is reported to occur in 0.5-9% of severe acute respiratory distress coronavirus 2-positive patients and AKI has been identified as an independent risk factor for in-hospital mortality. The present study aims to investigate the incidence of renal outcome of in-hospital patients diagnosed with COVID-19.
Description: As determined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria
Measure: Incidence of AKI Time: Within 7 days after admissionDescription: Serial biomarker assessment
Measure: Renal function changes during hospital stay Time: from hospital admission til discharge up to 3 monthsDescription: As determined by KDIGO criteria
Measure: Incidence of chronic kidney disease Time: 3 months post-hospital admissionAmong patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.
Description: Sensibility and specificity of urinary [TIMP-2]*[IGFBP-7] > 0,3 to predict AKI (KDIGO stage ≥ 1) in SARS-CoV-2 patients at day-7 after measurement
Measure: Sensibility and specificity of urinary Time: Occurence of AKI 7 days after urinary biomarkers measurementDescription: Sensibility and specificity of urinary [TIMP-2]*[IGFBP-7] > 0,3 to predict AKI worsening, renal replacement therapy requirement or persistant AKI
Measure: Sensibility and specificity of urinary Time: Occurnce of AKI worsening, renal replacement therapy requirement or persistant AKI, 7 days after urinary biomarkers mesurement